PGM is pleased to announce the enrollment of the twentieth patient in its IDE-approved clinical safety study for its Regenn™ Negative Pressure Therapy System (NPTS).  “We are pleased with our clinical experience of the Regenn™ NPTS and continue to work with the PGM team to bring this study to a successful completion”, Joshua Bunch, MD, Principle Investigator.  CEO, Neal Vail, said, “Patient enrollment is on track, putting us in a strong position to complete this study in the first half of 2026”.  San Antonio, TX, USA. December 2025.